Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Simcere Pharmaceutical Group EV-to-EBITDA?
Simcere Pharmaceutical GroupFRA:S2P +1.55%92 EV-to-EBITDA is 16.10 as of Aug. 15, 2026, which is 17% above its 10-year median of 13.73. GuruFocus rates FRA:S2P with a GF Score™ of 92/100 and a GF Value™ of €1.19 (Fairly Valued). Among 735 Drug Manufacturers companies, Simcere Pharmaceutical Group ranks worse than 58.78% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Simcere Pharmaceutical Group's enterprise value is €3,138.2 Mil.
Simcere Pharmaceutical Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €194.9 Mil. Therefore, Simcere Pharmaceutical Group's EV-to-EBITDA for today is 16.10.
The historical rank and industry rank for Simcere Pharmaceutical Group's EV-to-EBITDA or its related term are showing as below:
FRA:S2P'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.01 Med: 13.73 Max: 27.02
Current: 16.04
During the past 9 years, the highest EV-to-EBITDA of Simcere Pharmaceutical Group was 27.02. The lowest was 8.01. And the median was 13.73.
FRA:S2P's EV-to-EBITDA is ranked worse than 58.78% of 735
companies
in the Drug Manufacturers industry
Industry Median: 13.3
vs FRA:S2P: 16.04
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Simcere Pharmaceutical Group (FRA:S2P) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Simcere Pharmaceutical Group's PE Ratio (TTM) for today is calculated as:
Simcere Pharmaceutical Group's share price for today is €1.31.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Simcere Pharmaceutical Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.065.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simcere Pharmaceutical Group EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Simcere Pharmaceutical Group's EV-to-EBITDA falls into.
Simcere Pharmaceutical Group's current Enterprise Value is €3,138.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Simcere Pharmaceutical Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €194.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simcere Pharmaceutical Group (FRA:S2P) has a EV-to-EBITDA of 16.10 as of Aug. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Simcere Pharmaceutical Group. This is 17% above median its historical median of 13.73. Over the past decade, Simcere Pharmaceutical Group's EV-to-EBITDA has ranged from 8.01 to 27.02. According to the industry distribution chart, Simcere Pharmaceutical Group ranks #432 out of 735 companies in the Drug Manufacturers industry, placing it in the top 58.8%.
Is Simcere Pharmaceutical Group's EV-to-EBITDA too high?
Simcere Pharmaceutical Group's current EV-to-EBITDA of 16.10 is 17% above median its 10-year median of 13.73. Over the past 10 years, this metric has ranged from a low of 8.01 to a high of 27.02. The Drug Manufacturers industry median EV-to-EBITDA is 13.30. Simcere Pharmaceutical Group's value of 16.10 is 21.1% above this industry median. Based on the distribution chart, Simcere Pharmaceutical Group ranks #432 out of 735 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Simcere Pharmaceutical Group has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Simcere Pharmaceutical Group's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Simcere Pharmaceutical Group ranks #432 out of 735 companies for EV-to-EBITDA. This places Simcere Pharmaceutical Group in the lower half of its industry. The industry median EV-to-EBITDA is 13.30. Simcere Pharmaceutical Group's value of 16.10 is 21.1% above this benchmark. Historically, Simcere Pharmaceutical Group's own EV-to-EBITDA has ranged from 8.01 to 27.02 over the past decade. While the company's 10-year median is 13.73 vs. the industry median of 13.30, Simcere Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.30, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Simcere Pharmaceutical Group's current EV-to-EBITDA of 16.10 is 21.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Simcere Pharmaceutical Group. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simcere Pharmaceutical Group's current EV-to-EBITDA is 16.10, which is 17% above median its own 10-year median of 13.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simcere Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group (FRA:S2P) is currently considered Fairly Valued. The stock's GF Value™ is €1.19, compared to a current price of €1.31 — trading 10.1% above its estimated fair value. The current EV-to-EBITDA is 16.10, which is 17% above median its 10-year median of 13.73 and 21.1% above the Drug Manufacturers industry median of 13.30. Simcere Pharmaceutical Group's overall GF Score™ is 92/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Simcere Pharmaceutical Group (FRA:S2P), the current EV-to-EBITDA is 16.10 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simcere Pharmaceutical Group (FRA:S2P) Overvalued in 2026?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued.
The current stock price of €1.31 is trading 10.1% above its estimated GF Value™ of €1.19.
GuruFocus considers Simcere Pharmaceutical Group to be Fairly Valued.
Key valuation signals for FRA:S2P:
EV-to-EBITDA: 16.10 (17% above median its 10-year median of 13.73)
GF Value™: €1.19 vs. price of €1.31 (10.1% above fair value)
Industry Position: 21.1% above the Drug Manufacturers median (#432 of 735)
No single metric tells the full story. See the FRA:S2P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
92GF Score
Get the complete analysis for FRA:S2P
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:S2P has been successfully added to your 
